Get started
Eli Lilly and CompanyEli Lilly and CompanyEli Lilly and Company

Eli Lilly and Company

No trades
See on Supercharts
OverviewFinancialsNewsIdeasMindsTechnicalsForecastsSeasonalsBondsETFs

Chart


Full chart

Key facts today


Eli Lilly's weight-loss drug Zepbound saw $3.6 billion in Q3 sales, up 185% year-over-year, while Mounjaro generated $6.5 billion in the same period.
Eli Lilly's obesity drug, eloralintide, showed strong results in a Phase 2 trial, with participants losing 9.5% to 20.1% of weight. Phase 3 studies will start next month.
Eli Lilly's obesity pill, orforglipron, received a fast-track voucher from the FDA, speeding up the review process to one to two months instead of the usual 10 to 12 months.
Analyze the impactAnalyze the impact

Upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪761.65 B‬ EUR
Dividend yield (indicated)
0.65%
Price to earnings Ratio (TTM)
46.5
Basic EPS (TTM)
17.3 EUR
Net income (FY)
‪10.23 B‬ EUR
Revenue (FY)
‪43.51 B‬ EUR
Shares float
‪848.79 M‬
Beta (1Y)
0.60

Employees


Employees (FY)
‪47 K‬
Change (1Y)
‪+4 K‬ +9.30%
Revenue / Employee (1Y)
‪925.75 K‬ EUR
Net income / Employee (1Y)
‪217.65 K‬ EUR

About Eli Lilly and Company


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
David A. Ricks
Website
lilly.com
Headquarters
Indianapolis
Founded
1876
ISIN
US5324571083
FIGI
BBG000F48MY0
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Check out other big names from the same industry as LLY.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

News



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Highest yielding bonds


LLY4099975
Eli Lilly and Company 4.65% 15-JUN-2044
Yield to maturity
5.65%
Maturity date
Jun 15, 2044
XS238628644
Eli Lilly and Company 1.625% 14-SEP-2043
Yield to maturity
5.60%
Maturity date
Sep 14, 2043
LLY5871804
Eli Lilly and Company 5.2% 14-AUG-2064
Yield to maturity
5.49%
Maturity date
Aug 14, 2064
US532457BU1
Eli Lilly and Company 4.15% 15-MAR-2059
Yield to maturity
5.47%
Maturity date
Mar 15, 2059
LLY6153503
Eli Lilly and Company 5.65% 15-OCT-2065
Yield to maturity
5.46%
Maturity date
Oct 15, 2065
LLY5750032
Eli Lilly and Company 5.1% 09-FEB-2064
Yield to maturity
5.45%
Maturity date
Feb 9, 2064
LLY6003397
Eli Lilly and Company 5.6% 12-FEB-2065
Yield to maturity
5.45%
Maturity date
Feb 12, 2065
LLY5547405
Eli Lilly and Company 4.95% 27-FEB-2063
Yield to maturity
5.44%
Maturity date
Feb 27, 2063
LLY6003396
Eli Lilly and Company 5.5% 12-FEB-2055
Yield to maturity
5.39%
Maturity date
Feb 12, 2055
US532457BT4
Eli Lilly and Company 3.95% 15-MAR-2049
Yield to maturity
5.39%
Maturity date
Mar 15, 2049
US532457BY3
Eli Lilly and Company 2.25% 15-MAY-2050
Yield to maturity
5.38%
Maturity date
May 15, 2050

See all LLY bonds 

ETFs


VTI
Vanguard Total Stock Market ETF
Weight
1.01%
Market value
‪20.45 B‬
USD
VOO
Vanguard S&P 500 ETF
Weight
1.06%
Market value
‪14.95 B‬
USD
IVV
iShares Core S&P 500 ETF
Weight
1.30%
Market value
‪9.20 B‬
USD
SPY
SPDR S&P 500 ETF Trust
Weight
1.27%
Market value
‪8.85 B‬
USD
SPY
SPDR S&P 500 ETF
Weight
1.27%
Market value
‪8.85 B‬
USD
VUG
Vanguard Growth ETF
Weight
1.99%
Market value
‪6.80 B‬
USD
XLV
Health Care Select Sector SPDR Fund
Weight
13.93%
Market value
‪5.10 B‬
USD
VIG
Vanguard Dividend Appreciation ETF
Weight
2.82%
Market value
‪3.26 B‬
USD
IWF
iShares Russell 1000 Growth ETF
Weight
2.39%
Market value
‪2.95 B‬
USD
QUAL
iShares MSCI USA Quality Factor ETF
Weight
4.13%
Market value
‪2.14 B‬
USD
VHT
Vanguard Health Care ETF
Weight
10.33%
Market value
‪1.83 B‬
USD

Explore more ETFs 

Sparks


Curated watchlists where LLY is featured.

See all sparks 

Frequently Asked Questions


The current price of LLY is 808.0 EUR — it has decreased by −1.69% in the past 24 hours. Watch Eli Lilly and Company stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange Eli Lilly and Company stocks are traded under the ticker LLY.
LLY stock has risen by 15.16% compared to the previous week, the month change is a 11.25% rise, over the last year Eli Lilly and Company has showed a 12.00% increase.
We've gathered analysts' opinions on Eli Lilly and Company future price: according to them, LLY price has a max estimate of 1,035.55 EUR and a min estimate of 609.15 EUR. Watch LLY chart and read a more detailed Eli Lilly and Company stock forecast: see what analysts think of Eli Lilly and Company and suggest that you do with its stocks.
LLY reached its all-time high on Mar 3, 2025 with the price of 888.8 EUR, and its all-time low was 21.5 EUR and was reached on Mar 6, 2009. View more price dynamics on LLY chart.
See other stocks reaching their highest and lowest prices.
LLY stock is 0.53% volatile and has beta coefficient of 0.60. Track Eli Lilly and Company stock price on the chart and check out the list of the most volatile stocks — is Eli Lilly and Company there?
Today Eli Lilly and Company has the market capitalization of ‪758.06 B‬, it has decreased by −2.94% over the last week.
Yes, you can track Eli Lilly and Company financials in yearly and quarterly reports right on TradingView.
Eli Lilly and Company is going to release the next earnings report on Feb 11, 2026. Keep track of upcoming events with our Earnings Calendar.
LLY earnings for the last quarter are 5.98 EUR per share, whereas the estimation was 4.85 EUR resulting in a 23.33% surprise. The estimated earnings for the next quarter are 6.11 EUR per share. See more details about Eli Lilly and Company earnings.
Eli Lilly and Company revenue for the last quarter amounts to ‪15.00 B‬ EUR, despite the estimated figure of ‪13.68 B‬ EUR. In the next quarter, revenue is expected to reach ‪15.18 B‬ EUR.
LLY net income for the last quarter is ‪4.76 B‬ EUR, while the quarter before that showed ‪4.81 B‬ EUR of net income which accounts for −1.00% change. Track more Eli Lilly and Company financial stats to get the full picture.
Yes, LLY dividends are paid quarterly. The last dividend per share was 1.28 EUR. As of today, Dividend Yield (TTM)% is 0.63%. Tracking Eli Lilly and Company dividends might help you take more informed decisions.
Eli Lilly and Company dividend yield was 0.67% in 2024, and payout ratio reached 44.39%. The year before the numbers were 0.78% and 77.91% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Nov 7, 2025, the company has ‪47 K‬ employees. See our rating of the largest employees — is Eli Lilly and Company on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Eli Lilly and Company EBITDA is ‪24.11 B‬ EUR, and current EBITDA margin is 41.75%. See more stats in Eli Lilly and Company financial statements.
Like other stocks, LLY shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Eli Lilly and Company stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Eli Lilly and Company technincal analysis shows the buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Eli Lilly and Company stock shows the strong buy signal. See more of Eli Lilly and Company technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.